Stryker Q1 Sales Up 2.6% Miss Estimates

Stryker reported Q1 2026 net sales grew 2.6% year‑over‑year, below analyst expectations.
Adjusted earnings per share fell 8.5% to $2.60, also missing forecasts.
MedSurg and Neurotechnology segments posted 5.0% sales growth, while Orthopaedics was flat overall but saw 4.1% organic rise.
Company maintained FY2026 guidance of 8‑9.5% organic sales growth and $14.90‑$15.10 EPS, citing modest pricing and FX tailwinds.